Recent developments highlight Aibotics' strategic partnerships, product launches, and geographic expansion in AI robotics and psychedelics research.

• Aibotics partnered with KEENON Robotics to enter the Israeli market alongside Israeli Cannibble Food-Tech, expanding its global robotics footprint [N1].
• The company introduced intelligent service robotics in Tel Aviv, aiming to redefine human-machine interaction [N2].
• Aibotics signed a letter of intent to acquire Google partner NovaCore Labs and partnered with KEENON Robotics to bring XMAN and service robots to Jamaica and the CARICOM region [N3].
• KEENON Robotics shipped its first robots to Israel post-war under an agreement with Aibotics, initiating a Middle East robotics rollout [N4].
• KEENON Robotics, a leading global robotic manufacturer, signed a partnership agreement with Aibotics to collaborate on robotic products [N5].
• Aibotics launched its first pilot program with a Miami elite fitness center to introduce the Phill Robot in high-end recovery lounges [N6].
• The company issued a mid-year shareholder update highlighting corporate progress, technology development, and a strategic roadmap for agentic AI integration [N7].
• Aibotics targeted a Q2 2025 launch for the Phill Robot, the world's first AI massage robot, and announced a fitness center pilot program in Miami [N8].

Aibotics has developed innovative AI-powered robotic products targeting wellness and healthcare markets, including the Phill Robot and Milkyway smart refrigerator. Its partnerships with KEENON Robotics enable international distribution and manufacturing scale. The company's involvement in psychedelics research through supply agreements and data collection technology positions it to participate in emerging mental health treatment markets. Recent pilot programs and geographic expansion demonstrate operational progress and market engagement.

Aibotics faces significant financial challenges, including minimal revenue and substantial net losses, with liquidity ratios indicating limited short-term financial resources. The company's business model spans complex and highly regulated sectors such as psychedelics research and AI robotics, which involve regulatory risks and long development timelines. The early-stage status of its products and reliance on partnerships may constrain growth and operational execution. Market acceptance and regulatory approvals remain uncertain, posing risks to business sustainability.

Aibotics' moat is derived from its integration of AI technology with robotics in wellness and healthcare applications, supported by proprietary intellectual property such as the Phill Robot and Milkyway products. Strategic partnerships with established robotics manufacturer KEENON Robotics provide distribution channels and manufacturing capabilities. The company's focus on psychedelics research, supported by supply agreements and regulatory compliance, positions it in a niche market with potential for innovation. However, the early-stage nature of its products and financial constraints limit the current strength of its competitive advantages.

• Financial Risk: The company reported a net loss of $2,215,751 and very low revenue of $2,183 for the fiscal year ended December 31, 2025, with liquidity ratios (current ratio 0.06, cash ratio 0.09) indicating limited short-term financial resources [S1].
• Regulatory Risk: Aibotics operates in the psychedelics research sector, which is subject to complex and evolving regulatory frameworks including FDA oversight and controlled substances laws, potentially impacting research and commercialization activities [S1].
• Execution Risk: The company is in early stages of product development and market entry, relying on partnerships and pilot programs to establish its AI robotics products, which may face challenges in scaling and market acceptance [N2][N6][S1].

• Aibotics, Inc. is a Nevada corporation focused on promoting the study of psychedelics for mental health treatment and developing AI-powered robotics products, including the Phill Robot and Milkyway smart refrigerator [S1].
• The company acquired assets from Philon Labs, including intellectual property for the Phill Robot (an AI-powered massage robot) and Milkyway (a smart breast milk storage refrigerator) [S1].
• Aibotics has a supply agreement with HAVN Life Sciences to obtain naturally derived psilocybin for research and development purposes [S1].
• The company leverages technology from its parent company, Ehave, Inc., to collect research and clinical data related to psychedelics and mental health [S1].
• Aibotics has entered into partnerships with KEENON Robotics, a global leader in robotic manufacturing, to distribute service robots in various regions including Israel, Jamaica, and the Caribbean [N1][N3][N4][N5].
• The Phill Robot is designed as a compact, AI-controlled massage device with patented deployment and a range of massage patterns, targeting the wellness market [S1].
• The Milkyway product features a patent-pending vertical rotating storage system for breast milk, customizable for home or hospital use, with app integration for monitoring [S1].
• Recent news highlights include pilot programs for the Phill Robot in Miami fitness centers and expansion of intelligent service robotics in Tel Aviv [N2][N6].
• Financial snapshot as of December 31, 2025, shows very low revenue of $2,183 USD and a net loss of $2,215,751 USD [S1].
• Liquidity ratios as of December 31, 2025, indicate a current ratio of 0.06 and a cash ratio of 0.09, reflecting limited short-term financial resources [S1].
• The company issued Series B Preferred Stock as consideration for the Philon Labs asset acquisition and has revenue-based incentives for employees tied to sales generated by these assets [S1].
• Aibotics does not manufacture or sell psilocybin directly but supports research and development in compliance with regulatory frameworks [S1].